NFKB1 and colitis: Furthermore, COX seems to be a downstream of NF-κB (48), so it might be reasonable that mesalazine, a COX inhibitor, ameliorates colitis without significant inhibition of p-p65 but decreased production of the pro-inflammatory cytokines.